Acrux logo

ACR - Acrux Share Price

A$0.115 0.0  4.6%

Last Trade - 27/03/20

Sector
Healthcare
Size
Micro Cap
Market Cap £9.53m
Enterprise Value £3.57m
Revenue £1.60m
Position in Universe 1091st / 1841
Bullish
Bearish
Unlock ACR Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ACR Revenue Unlock ACR Revenue

Net Income

ACR Net Income Unlock ACR Revenue

Normalised EPS

ACR Normalised EPS Unlock ACR Revenue

PE Ratio Range

ACR PE Ratio Range Unlock ACR Revenue

Dividend Yield Range

ACR Dividend Yield Range Unlock ACR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ACR EPS Forecasts Unlock ACR Revenue
Profile Summary

Acrux Limited is a drug development company. The Company is engaged in developing and commercializing branded and generic transdermal and topical pharmaceuticals for global markets. The Company's transdermal or topical pharmaceutical product portfolio can be segregated into approximately two streams, such as generic pharmaceutical products and specialty pharmaceutical products. The Company's products include Axiron, Ellavie, Evamist and Lenzetto. Axiron (testosterone) topical solution CIII is a testosterone topical solution approved for application via an armpit (underarm) applicator. It has developed the estradiol spray for women, used to treat moderate to severe hot flushes commonly associated with menopause. In the United States, the Company's estradiol spray is branded Evamist. The Company has licensed its estradiol product to Gedeon Richter to commercialize in various territories, including Europe and Eurasia. Gedeon Richter has branded the estradiol spray as Lenzetto.

Directors
Last Annual June 30th, 2019
Last Interim December 31st, 2019
Incorporated March 19, 1998
Public Since September 29, 2004
No. of Shareholders: 5,856
No. of Employees: 43
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 166,772,711
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ACR Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ACR
Upcoming Events for ACR
Similar to ACR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.